Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Chronic Hepatitis C: early-phase trial registry

A small indexed set (17 trials) with no open enrollment listed right now.

Corpus placement: #1,004 of 28,707 conditions by registered trial count.

17 US clinical trials · none currently recruiting · #1,004 of 28,707 conditions by registered trial count

Chronic Hepatitis C: 17 US clinical trials tracked, none currently recruiting.

Chronic Hepatitis C is the subject of 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 4 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 4 of these trials.

Enrollment posture brief

Registry condition chronic-hepatitis-c

OPEN 0 | RECR 0% | LATE 4 | EARLY 11 | RANK #1004 | SPON 4

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Myeloid Leukemia, in R70.6%Abdominal Aortic Aneurysm52.9%Acute Lymphoblastic Leukemia23.5%Actinic Keratosis11.8%Chronic Hepatitis C (this)0%
Open-enrollment share among volume-matched conditions near Chronic Hepatitis C

Chronic Hepatitis C has no open enrollment in this registry pull (17 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Hepatitis C on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Hepatitis C is recruiting below its size-band peers.

    0 of 17 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Chronic Hepatitis C research.

    Bristol-Myers Squibb accounts for 4 of 17 trials (23.5%). 13 distinct sponsors appear on at least one study for this condition label.

  3. Most Chronic Hepatitis C trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.

  4. Chronic Hepatitis C research is mostly interventional.

    15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 26Phase 33Phase 41

Indexed trials (enrollment closed)

17 total, page 1 of 1

COMPLETED Phase 3 1,050 participants

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00006164

COMPLETED Phase 3 933 participants

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Human Genome Sciences

NCT00411385

COMPLETED Phase 3 534 participants

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Gilead Sciences

NCT01625338

COMPLETED Phase 2 320 participants

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Bristol-Myers Squibb

NCT01455090

COMPLETED Phase 2 154 participants

Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment

National Center for Complementary and Integrative Health (NCCIH)

NCT00680342

COMPLETED Phase 1 95 participants

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Bristol-Myers Squibb

NCT00546715

COMPLETED Phase 2 50 participants

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Debiopharm International

NCT00537407

COMPLETED Phase 1 47 participants

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Bristol-Myers Squibb

NCT00983957

COMPLETED Phase 4 40 participants

Pioglitazone in Hepatitis C

University of Michigan

NCT00189163

COMPLETED Phase 2 40 participants

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

Bader, Ted, M.D.

NCT00487318

COMPLETED Phase 2 35 participants

New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT01888900

COMPLETED Phase 1 34 participants

Q-Trial in Patients With Hepatitis C

University of California, Los Angeles

NCT01438320

COMPLETED Phase 2 25 participants

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Trek Therapeutics, PBC

NCT02716428

COMPLETED Phase 1 24 participants

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Bristol-Myers Squibb

NCT00664625

COMPLETED 20 participants

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

Duke University

NCT02006823

COMPLETED 12 participants

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

SciClone Pharmaceuticals

NCT01310205

COMPLETED Phase 1 12 participants

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Pfizer

NCT01210404

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 6
Phase 3 3
Phase 4 1

Named interventions

Most-linked intervention names on Chronic Hepatitis C records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ribavirin Drug
4 trials
BMS-791325 Drug
2 trials
BMS-790052 Drug
2 trials
Placebo Drug
2 trials
fluvastatin Drug
1 trials
standard of care Drug
1 trials
Faldaprevir Drug
1 trials
Silymarin Drug
1 trials

US sites by state

Facility locations filed on Chronic Hepatitis C trials. A trial with sites in several states counts in each.

California 10 trials
Maryland 6 trials
Florida 6 trials
Texas 5 trials
Colorado 4 trials
Virginia 3 trials
Pennsylvania 3 trials
Massachusetts 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Hepatitis C page

17 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Chronic Hepatitis C trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bristol-Myers Squibb sponsors the most Chronic Hepatitis C trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Hepatitis C condition card totals 17 registered trials; most-linked intervention Ribavirin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.